CN110170007B - Composition for inhibiting pigmentation in skin healing process and preparation method and application thereof - Google Patents
Composition for inhibiting pigmentation in skin healing process and preparation method and application thereof Download PDFInfo
- Publication number
- CN110170007B CN110170007B CN201910242086.1A CN201910242086A CN110170007B CN 110170007 B CN110170007 B CN 110170007B CN 201910242086 A CN201910242086 A CN 201910242086A CN 110170007 B CN110170007 B CN 110170007B
- Authority
- CN
- China
- Prior art keywords
- parts
- pigmentation
- mineral powder
- composition
- healing process
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a composition for inhibiting pigmentation in a skin healing process, a preparation method and an application thereof, wherein the composition comprises the following components in parts by weight: 3-14 parts of bioactive mineral powder, 0.3-5 parts of VE and 8-16 parts of grape seed oil; wherein, the bioactive mineral powder comprises the following components in parts by weight: SiO 2230-85 parts of Na2O5-30 parts, CaO20-60 parts and P2O50-2 parts of. The composition for inhibiting the pigmentation in the skin healing process has simple components, has no side effect on human bodies, and has obvious inhibiting effect on the pigmentation in the skin healing process, particularly the pigmentation caused by anoxic pigmentation, accumulated pigments and inflammation; the composition for inhibiting pigmentation in the skin healing process has the advantages of simple preparation method, easily obtained and cheap raw materials, simple required conditions and equipment, simple and controllable process and important practical popularization value.
Description
Technical Field
The invention relates to a pharmaceutical composition for treating skin, in particular to a composition for inhibiting pigmentation in a skin healing process, a preparation method and application thereof.
Background
The wound healing process is a control process in which a series of physiological changes and cells, cytokines, extracellular matrix and the like participate in regulation, and in the process, various pathological and physiological factors can influence and change the physiological healing process, so that scars are formed, and the formation of the scars is a process which participates in a plurality of cytokines, genetic mechanisms and the like.
At present, there is no unified classification of scars, which can be generally classified into superficial scars, hypertrophic scars, atrophic scars, keloids, cancer scars, etc. At present, physical therapy, surgical therapy and drug therapy are common in the treatment of scars and the like, and comprehensive treatment and other methods are generally adopted clinically.
After being injured, the wound surface can seep blood and tissue fluid, combine dead and fallen cells and the like to form a layer of hard crusty skin, and stimulate the skin to generate itching. If the crust is stimulated or disturbed, it will take away the epidermal cells in the repair phase, even damaging the dermis and stimulating local inflammatory reactions, which may result in scarring and pigmentation. If the new tissue is further stimulated by the outside in the healing process, local subdermal capillary vessel dilatation and granulation tissue hyperplasia can be stimulated to form pigmentation scars. In addition, the stratum corneum on the surface of the skin is densely packed, and the subcutaneous melanin metabolism of the skin is also disturbed, so that pigmentation is caused.
The bioactive mineral powder is an important inorganic bioactive material, has a special inorganic amorphous structure, has excellent performances of improving cell activity, promoting biomineralization and the like, and is a tissue repair material with better performance than other crystalline bioactive materials. Bioactive mineral powders, the composition of which comprises SiO, were first discovered in 1969 by professor Hench2、Na2O、CaO、P2O5And the like. The degradation product of the bioactive mineral powder can promote the generation of growth factors, promote the multiplication of cells and enhance the gene expression of the cells and the growth of soft tissues, is the only artificial biomaterial which can be bonded with bone tissue and can be connected with the soft tissues so far, and is considered as a good biomaterial which can be applied to the field of repair. The bioactive mineral powder has wide application and magical effect which cannot be replaced on professional products in various fields. With the research on the bioactive mineral powder, the bioactive mineral powder has been widely applied to the medical field, such as bone tissue repair, skin tissue repair, prevention and treatment of oral diseases, and the like.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a composition for inhibiting pigmentation in a skin healing process, and a preparation method and application thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a composition for inhibiting pigmentation in a skin healing process comprises the following components in parts by weight:
3-14 parts of bioactive mineral powder, 0.3-5 parts of VE and 8-16 parts of grape seed oil;
wherein the bioactive mineral powder comprises the following components in parts by weight:
SiO230-85 parts of Na2O5-30 parts, CaO20-60 parts and P2O50-2 parts of.
On the basis of the bioactive mineral powder, VE and grape seed oil are further added, so that the purposes of quickly inhibiting skin pigment deposition, promoting skin pigment-free healing and repairing damaged skin or mucosal tissue can be effectively achieved.
Preferably, in the above technical scheme, the composition comprises the following components in parts by weight:
5-7.5 parts of bioactive mineral powder, 0.8-1.5 parts of VE and 10-13.5 parts of grape seed oil.
In order to match the interaction with VE and grape seed oil, the invention researches and discovers that the bioactive mineral powder adopting the following formula has very obvious effect on the basis of the formula of the existing bioactive mineral powder;
the bioactive mineral powder comprises the following components in parts by weight:
SiO240-65 parts of Na28-20 parts of O, 20-60 parts of CaO and P2O50-1 part.
Further, in the above technical scheme, the particle size of the bioactive mineral powder is 0.1-60 microns, and the crystallization rate is lower than 5%.
The invention is directed specifically to the unique wound healing process of skin and mucosal soft tissues, developing a more effective bioactive mineral powder for soft tissues. On one hand, on the basis of the traditional core 45S5 general component, the interference of elements such as phosphorus and the like on fibroblasts is reduced to cause hypertrophic scars, and simultaneously, the contents of sodium and calcium elements are reduced, and the pH value is reduced, so that the stimulation of the component on neutral and acidic skin is reduced, and the promotion effect of the component on the soft tissue repair is not influenced. In the process of wound healing, the blood circulation of a wound part is limited due to the problems of blood coagulation, limited blood circulation, large amount of inflammatory cells aggregation, accumulation of various cells and the like, pigments such as melanin, blood clots and the like cannot be effectively metabolized, and the pigments are deposited for a long time.
In the scheme of the invention, the bioactive mineral powder mainly plays roles of sterilizing and inhibiting bacteria, promoting the growth of fibroblasts and epithelial cells and accelerating the repair process of skin or mucosa; vitamin E has the functions of reducing oxygen consumption of cells, ensuring the state of high cell activity and durability, resisting oxidation, reducing free radical interference on newborn cells, ensuring that the cells can keep normal blood transport capacity under severe conditions, keeping the normal metabolic capacity of an organism to various pigments, and reducing pigment deposition and dark state; the grape seed oil can also assist VE to eliminate the interference of the problems of free radicals and the like at wound parts on cells, assist in improving the blood circulation capability and the metabolic capability of newborn tissues, simultaneously provide a large amount of nutrients such as amino acid and the like for the newborn cells, effectively relieve the newborn cells and reduce the occurrence of the problem of sensitivity of newborn skin. The three have synergistic effect.
Still further, in the above technical solution, the composition further comprises a carrier, wherein the carrier is one or more selected from glycerol, PEG and olive oil, and is preferably glycerol.
Preferably, in the above technical solution, the weight ratio of the bioactive mineral powder to the carrier is 1: 5-24.
Still further, in the above technical solution, the composition further comprises a thickener, the thickener is one or more selected from carbomer, CMC, xanthan gum, sodium alginate and sodium hyaluronate, and preferably carbomer.
Preferably, in the above technical solution, the addition amount of the thickener is 0.01-0.07 times of the mass of the carrier.
The invention further provides a more preferable scheme, and the composition comprises the following components in parts by weight:
5.5-7.5 parts of bioactive mineral powder, 0.8-1.2 parts of VE, 10-12.5 parts of grape seed oil, 75-80 parts of carrier and 0.8-1.6 parts of thickening agent.
The invention also aims to provide a preparation method of the composition, which comprises the step of uniformly mixing the bioactive mineral powder, the VE and the grape seed oil.
In the technical scheme, the preparation method comprises the steps of dispersing the thickening agent into a carrier, fully stirring and swelling, then adding the bioactive mineral powder, VE and grape seed oil, and uniformly stirring.
The composition of the present invention has a remarkable effect in inhibiting pigmentation in the skin healing process, particularly, hypoxic pigmentation, accumulation type pigmentation and inflammation-induced pigmentation.
The invention has the beneficial effects that:
(1) the composition for inhibiting the pigmentation in the skin healing process has simple components, has no side effect on human bodies, and has obvious inhibition effect on the pigmentation in the skin healing process, particularly the hypoxic pigmentation, the accumulation type pigment and the pigmentation caused by inflammation;
(2) the composition for inhibiting pigmentation in the skin healing process has the advantages of simple preparation method, easily available and cheap raw materials, simple required conditions and equipment, simple and controllable process and very important practical popularization value.
Detailed Description
The following describes the embodiments of the present invention in further detail with reference to specific examples.
The following examples are intended only to further illustrate the present invention and should not be construed as limiting the invention. Modifications or substitutions to methods, procedures, or conditions of the invention may be made without departing from the spirit and scope of the invention.
The raw materials used in the examples of the present invention and the comparative examples are commercially available products.
Unless otherwise specified, the technical means used in the examples of the present invention are conventional means well known to those skilled in the art.
EXAMPLE 1A composition for inhibiting pigmentation in skin healing process
1. The raw material ratio is as follows:
the bioactive mineral powder comprises the following components in parts by weight: SiO 2255 parts of Na220 portions of O, 25 portions of CaO and P2O51.6 parts.
2. The preparation method comprises the following steps:
s1, respectively weighing bioactive mineral powder, VE, grape seed oil, glycerol and carbomer according to the proportion for later use;
and S2, dispersing carbomer into glycerol, fully stirring and swelling, then adding the bioactive mineral powder, VE and grape seed oil, and uniformly stirring.
Example 2A composition for inhibiting pigmentation in skin healing process
1. The raw material ratio is as follows:
the bioactive mineral powder comprises the following components in parts by weight: SiO 2260 portions of Na215 portions of O, 25 portions of CaO and P2O51.5 parts.
2. The preparation method comprises the following steps:
s1, respectively weighing bioactive mineral powder, VE, grape seed oil, glycerol and carbomer according to the proportion for later use;
and S2, dispersing carbomer into glycerol, fully stirring and swelling, then adding the bioactive mineral powder, VE and grape seed oil, and uniformly stirring.
EXAMPLE 3A composition for inhibiting pigmentation during skin healing
1. The raw material ratio is as follows:
the bioactive mineral powder comprises the following components in parts by weight: SiO 2260 portions of Na215 portions of O, 25 portions of CaO and P2O50.6 part.
2. The preparation method comprises the following steps:
s1, respectively weighing bioactive mineral powder, VE, grape seed oil, glycerol and carbomer according to the proportion for later use;
and S2, dispersing carbomer into glycerol, fully stirring and swelling, then adding the bioactive mineral powder, VE and grape seed oil, and uniformly stirring.
Example 4A composition for inhibiting pigmentation during skin healing
1. The raw material ratio is as follows:
the bioactive mineral powder comprises the following components in parts by weight: SiO 2260 portions of Na215 portions of O, 25 portions of CaO and P2O50.4 part.
2. The preparation method comprises the following steps:
s1, respectively weighing bioactive mineral powder, VE, grape seed oil, glycerol and carbomer according to the proportion for later use;
and S2, dispersing carbomer into glycerol, fully stirring and swelling, then adding the bioactive mineral powder, VE and grape seed oil, and uniformly stirring.
EXAMPLE 5A composition for inhibiting pigmentation in skin healing process
1. The raw material ratio is as follows:
the bioactive mineral powder comprises the following components in parts by weight: SiO 2260 portions of Na215 portions of O, 25 portions of CaO and P2O51.5 parts.
2. The preparation method comprises the following steps:
s1, respectively weighing bioactive mineral powder, VE, grape seed oil, glycerol and carbomer according to the proportion for later use;
and S2, dispersing carbomer into glycerol, fully stirring and swelling, then adding the bioactive mineral powder, VE and grape seed oil, and uniformly stirring.
Comparative example 1A composition for inhibiting pigmentation during skin healing
1. The raw material ratio is as follows:
the bioactive mineral powder comprises the following components in parts by weight: SiO 2255 parts of Na220 portions of O, 25 portions of CaO and P2O51.6 parts.
2. The preparation method comprises the following steps:
s1, respectively weighing bioactive mineral powder, sodium hyaluronate, grape seed oil, glycerol and carbomer according to the proportion for later use;
s2, dispersing carbomer into glycerol, fully stirring and swelling, then adding the bioactive mineral powder, the sodium hyaluronate and the grape seed oil, and uniformly stirring.
Comparative example 2A composition for inhibiting pigmentation during skin healing
1. The raw material ratio is as follows:
the bioactive mineral powder comprises the following components in parts by weight: SiO 2245 parts of Na2O24 parts, CaO24 parts, P2O56 parts of (1); k2And O1 part.
2. The preparation method comprises the following steps:
s1, respectively weighing bioactive mineral powder, VE, grape seed oil, glycerol and carbomer according to the proportion for later use;
and S2, dispersing carbomer into glycerol, fully stirring and swelling, then adding the bioactive mineral powder, VE and grape seed oil, and uniformly stirring.
Comparative example 3 this comparative example 3 provides a homogeneous mixture of only VE 1 part and grape seed oil 12 parts of example 1.
Comparative example 4 this comparative example 4 only provides 6 parts of the bioactive mineral powder of example 1.
Experimental example 1
The compositions or specific compounds provided in examples 1-5 and comparative examples 1-4 were subjected to experimental comparisons:
animal model:
after the animal skin preparation, it was sterilized with iodine-alcohol, a region 15mm in diameter was marked at the center of the skin preparation with a medical marker, and the spot-forming liquid was injected into the subcutaneous region at uniform multiple points by a sterile microneedle injector. Lightly rubbing the injection area with spot forming liquid every day, irradiating with ultraviolet light for 1min, and operating for three days; and then the medicine is smeared twice a day, and the smearing mode is that 2g of medicine is smeared on the wound surface after debridement in the morning and evening every day.
The healing was recorded after 20 days of observation and the results are shown in table 1 below.
TABLE 1 results of experimental treatment of samples prepared in each example and comparative example
Experimental example 2 cytotoxicity assay
Sample preparation: 2g of the prepared sample is added into 10ml of MEM culture solution containing fetal calf serum, the mixture is fully mixed and then is leached for 24 hours in a thermostat at 37 +/-2 ℃, and then the mixture is stood to obtain supernatant.
The supernatant obtained above was used for contact culture of mouse fibroblasts (L-929), and the degree of cell proliferation was compared by MTT colorimetry at 2 days, 4 days and 7 days, respectively, to examine the degree of toxicity to cells.
The toxicity criteria are shown in table 2 below.
TABLE 2 toxicity criteria
From the experimental results, it can be seen that the samples prepared in examples 1 to 5 have relatively small irritation to cells, are substantially 0 grade, have no obvious irritation, and have a tendency of increasing the MTT value with the increase of the experimental time, indicating that the irritation is gradually reduced. That is, the components of the composition prepared in the embodiments of the present invention are advantageous in reducing the sensitivity and inflammatory response of mucosal cells or epithelial cells to the composition, and are more suitable for long-term use of skin and mucosal tissues. On the one hand, the pH value of the formula of the bioactive mineral powder adopted by the invention is slightly lower than that of a control group, so that the bioactive mineral powder is more suitable for the growth and reproduction of cells, and meanwhile, the formula of the bioactive mineral powder adopted by the invention is more systematically coordinated with the formula of the composition, so that the bioactive mineral powder can promote the growth and reproduction of cells and has a synergistic effect.
Although the invention has been described in detail hereinabove by way of general description, specific embodiments and experiments, it will be apparent to those skilled in the art that many modifications and improvements can be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (6)
1. The composition for inhibiting pigmentation in the skin healing process is characterized by comprising the following components in parts by weight:
5.5-7.5 parts of bioactive mineral powder, 0.8-1.2 parts of VE, 10-12.5 parts of grape seed oil, 75-80 parts of carrier and 0.8-1.6 parts of thickening agent;
wherein the bioactive mineral powder comprises the following components in parts by weight:
SiO2 40-65 parts of Na28-20 parts of O, 20-60 parts of CaO and P2O50.4-1 part.
2. The composition according to claim 1, wherein the bioactive mineral powder has a particle size of 0.1-60 microns and a crystallization rate of less than 5%.
3. The composition according to claim 1 or 2, wherein the carrier is selected from one or more of glycerol, PEG and olive oil.
4. A composition according to claim 1 or 2, wherein the thickening agent is selected from one or more of carbomer, CMC, xanthan gum, sodium alginate and sodium hyaluronate.
5. A method for preparing the composition of any of claims 1-4, comprising dispersing the thickening agent in a carrier, stirring and swelling thoroughly, then adding the bioactive mineral powder, VE and grapeseed oil, and stirring well.
6. Use of a composition according to any of claims 1 to 4 for the preparation of a product for inhibiting pigmentation in the healing process of the skin, wherein the pigmentation is a stacked pigmentation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910242086.1A CN110170007B (en) | 2019-03-28 | 2019-03-28 | Composition for inhibiting pigmentation in skin healing process and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910242086.1A CN110170007B (en) | 2019-03-28 | 2019-03-28 | Composition for inhibiting pigmentation in skin healing process and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110170007A CN110170007A (en) | 2019-08-27 |
| CN110170007B true CN110170007B (en) | 2021-08-31 |
Family
ID=67689015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910242086.1A Active CN110170007B (en) | 2019-03-28 | 2019-03-28 | Composition for inhibiting pigmentation in skin healing process and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110170007B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1207753A (en) * | 1995-11-09 | 1999-02-10 | 威廉·邦菲尔德 | Bioactive composite material for repair of hard and soft tissues |
| CN104147051A (en) * | 2014-08-15 | 2014-11-19 | 北京刷新活力健康科技有限公司 | Multiple-effect skin health composition and preparation thereof |
| CN105107014A (en) * | 2015-08-26 | 2015-12-02 | 东莞市达庆医疗器械有限公司 | Medical biological anti-allergy dressing for skins and method for preparing medical biological anti-allergy dressing |
| CN105169458A (en) * | 2015-09-25 | 2015-12-23 | 胡方 | Biological activity mineral substance material and application of biological activity mineral substance material to soft tissue anabrosis and long-time erosion wound cell regeneration and melanoma restraining |
-
2019
- 2019-03-28 CN CN201910242086.1A patent/CN110170007B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1207753A (en) * | 1995-11-09 | 1999-02-10 | 威廉·邦菲尔德 | Bioactive composite material for repair of hard and soft tissues |
| CN104147051A (en) * | 2014-08-15 | 2014-11-19 | 北京刷新活力健康科技有限公司 | Multiple-effect skin health composition and preparation thereof |
| CN105107014A (en) * | 2015-08-26 | 2015-12-02 | 东莞市达庆医疗器械有限公司 | Medical biological anti-allergy dressing for skins and method for preparing medical biological anti-allergy dressing |
| CN105169458A (en) * | 2015-09-25 | 2015-12-23 | 胡方 | Biological activity mineral substance material and application of biological activity mineral substance material to soft tissue anabrosis and long-time erosion wound cell regeneration and melanoma restraining |
Non-Patent Citations (1)
| Title |
|---|
| 葡萄籽功能性成分及其应用;吴嘉慧等;《日用化学工业》;20110630;第41卷(第3期);第216-221页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110170007A (en) | 2019-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101780031B (en) | Induced gel used for repairing skin wound surfaces or cervical mucosa | |
| CN113332162B (en) | protamine-PDRN compound, composition and application in preparation of skin care product | |
| CN103736080B (en) | For the preparation of wound healing, preparation method and its usage | |
| CN110974781A (en) | Gel for repairing skin wound | |
| CN1164276C (en) | Method of in vitro culturing medicine ox gallstone with natural ox gall | |
| CN110170007B (en) | Composition for inhibiting pigmentation in skin healing process and preparation method and application thereof | |
| CN109793757B (en) | Composition for inhibiting growth of skin scar and preparation method and application thereof | |
| RU2292212C1 (en) | Conditioning medium with therapeutic effect | |
| CN1309426C (en) | Application of biological active glass in the preparation process of ulcer and erosion wound treating dressing | |
| US20200061125A1 (en) | Treatment and compound for epithelial wounds | |
| US10232004B2 (en) | Pharmaceutical composition based on Centella asiatica (Hydrocotyle asiatica L.) for the treatment of lower limb ulcers | |
| CN107468715A (en) | Bacillus cercus CGMCC0601 zymotic fluids are preparing the application in treating diabetes trauma Wound medicine | |
| JPWO2004075906A1 (en) | Anti-inflammatory agent and anti-inflammatory medical material | |
| JP7364839B2 (en) | Use of cannaflavin A in the manufacture of pharmaceutical products promoting wound healing | |
| CN117138028B (en) | Composition containing epidermal stem cell factor and application thereof in diabetic foot repair | |
| WO2004089430A1 (en) | New dressing material promoting recovery of skin wound | |
| CN1072499C (en) | External-use medicine for curing various chronic ulcers | |
| CN111803622A (en) | Liquid repairing film for oral ulcer | |
| To’raeva | OF EFFECTIVENESS OF TREATMENT OF GENERALIZED PERIODONTITIS USING AUTOMOTOMBOCITAR MASS | |
| CN117138027B (en) | Gel containing epidermal stem cell factor and application of gel in scar repair | |
| CN110420199A (en) | It is a kind of for wound healing and the water gel of cosmetics and its preparation method and application | |
| CN114344452B (en) | Scar-preventing burn ointment and preparation method and application thereof | |
| CN109106799A (en) | It is a kind of to contain conjugated linoleic acid, organic zinc, the myogenic cream of peptide components and preparation method thereof | |
| CN101366922B (en) | Proprietary Chinese medicine for treating empyrosis | |
| CN110433236B (en) | Traditional Chinese medicine composition for promoting wound healing and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |